S
Scientia Vascular
Innovative neurovascular devices utilizing advanced micromachining for precise clot removal and smoother navigation
About Scientia Vascular
Scientia Vascular, founded in 2007 and headquartered in Salt Lake City, specializes in developing advanced neurovascular devices. The company leverages cutting-edge micromachining technology to create high-precision guidewires and catheters, primarily serving healthcare providers in the neurovascular treatment space. Their flagship products, such as the Colossus Guidewire and the 38 Aspiration Catheter, are designed to minimize the ledge effect and enhance navigation through the vasculature, thereby improving clot removal outcomes. Scientia Vascular operates in the medical technology market, focusing on innovation and quality to maintain a competitive edge. The company generates revenue through the sale of its FDA-cleared medical devices, targeting hospitals and specialized medical centers. Key milestones include the FDA clearance of their first product in 2014 and subsequent advancements in microfabrication technology. The company benefits from its strategic location in Salt Lake City, which offers access to a rich talent pool and a burgeoning medical technology sector.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- West Valley City, United States
- Employees
- 166
- Open positions
- 18
- Dealroom signal
- 73.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Medical & Healthcare, Surgery, Neurology, Catheters, Surgical Equipment, Tech for Hospitals and Clinics, biotech medtech and e-health, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2026 | $550M | $550M | Medtronic | ↗ |
| LATE VCOther financing | Sep 2024 | $14M | $56M | Piper Sandler | ↗ |
Growth signals
Latest recorded traffic for Scientia Vascular is 3.8K monthly website visits, up 46.2% over the last three months. Scientia Vascular's team declined 0.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Vivo Capital
Armentum Partners
Piper Sandler
Other known investors1 additional known investor
Medtronic
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scientia Vascular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scientia Vascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.